Bladder cancer has been billed by AstraZeneca as a key growth area for its immunotherapy Imfinzi, an ambition that has now been buoyed by the results of the VOLGA trial. VOLGA was conducted in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results